Abnormal Liver Function and Blood Lipid Indicators
Conditions
Interventions
Experimental Group:Hong In Tong Golden Bile Liver Care Capsules, Take 2 capsules once a day for a treatment period of 30 days
Sponsors
Guangzhou Eighth Peoples Hospital Guangzhou Medical University
Eligibility
Sex/Gender
All
Age
25 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1.Aged between 25 and 60 years old (inclusive), with no gender restriction; 2.Abnormal levels of serum aspartate aminotransferase (AST), alanine aminotransferase (ALT) and gamma-glutamyl transferase (GGT); 3.At least one abnormal item in blood lipid indicators (TC, TG, LDL-C, HDL-C); 4.Able to read Chinese and fully understand the trial procedures; 5.Willing to participate voluntarily and sign the informed consent form for the trial.
Exclusion criteria
Exclusion criteria: 1.Patients complicated with diseases of vital organs including the heart, liver, lungs and kidneys, hematological diseases, neoplastic diseases, etc; 2.Subjects diagnosed with viral hepatitis, drug-induced hepatitis, autoimmune liver disease or fatty liver caused by the above conditions; those complicated with hepatitis B, hepatitis C, liver cirrhosis and primary liver cancer; 3.Subjects with severe mental illnesses who are unable to control their behaviors or cooperate with the trial; 4.Patients who have taken any drugs that may interfere with the trial within the past 3 months, including hypoglycemic agents, colchicine, penicillamine, corticosteroids, ursodeoxycholic acid, pentoxifylline, long-term non-steroidal anti-inflammatory drugs, statins, antipsychotics, anticonvulsants, and high-dose paracetamol (= 2.5 g/day), etc; 5.Subjects who have taken lipid-lowering drugs within the past 3 months, excluding those who have used such drugs for more than 3 consecutive months with stable blood lipid levels; 6.Subjects who received treatments that may affect liver function within the past 1 month; 7.People with allergic diathesis or potential allergies to ingredients of the test product; 8.Pregnant women, women planning to become pregnant, and breastfeeding women; 9.Subjects who have participated in or are currently involved in other clinical studies within the past 3 months; 10.Those deemed ineligible for this trial or likely to be lost to follow-up as assessed by the investigators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum Aminotransferases (Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Gamma-Glutamyl Transferase (GGT));Adverse events; | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum oxidative stress levels (MDA, SOD);Serum inflammatory markers (CRP, TNF-a, IL-6);BMI index;Urine Routine;Four items of blood lipid (Total Cholesterol(TC), High-Density Lipoprotein Cholesterol(HDL-C), Low-Density Lipoprotein Cholesterol(LDL-C), Triglycerides(TG));Liver stiffness and degree of hepatic steatosis;Blood routine;General clinical sympton assessment;Blood Biochemical Test (Albumin, Total Bilirubin, Direct Bilirubin, Serum Creatinine, Blood Urea Nitrogen, Uric Acid);Urine pregnancy test: for women of childbearing age only; | — |
Countries
China
Contacts
Public ContactHan Yajuan
Guangzhou Eighth Peoples Hospital Guangzhou Medical University
Outcome results
None listed